Todd Alfred Carter net worth and biography

Todd Carter Biography and Net Worth

Chief Scientific Officer of Voyager Therapeutics

Dr. Carter has served as our Chief Scientific Officer since September 2022. He previously served as our Senior Vice President of Research from March 2022 to September 2022, our Vice President of Research from November 2018 to March 2022, and as our Senior Director, Neuroscience from June 2016 to November 2018. Prior to joining us in 2016, Dr. Carter served as the Senior Science Advisor to the Office of the Director of the Broad Institute of MIT and Harvard. Previously, he oversaw research at BrainCells Inc. as Senior Director of Biology. Dr. Carter received a B.A. in genetics from Texas A&M University and a Ph.D. in genetics from Columbia University, and he completed his postdoctoral training at the Salk Institute for Biomedical Research.

What is Todd Alfred Carter's net worth?: The estimated net worth of Todd Alfred Carter is at least $452.45 thousand as of February 24th, 2026. Dr. Carter owns 145,718 shares of Voyager Therapeutics stock worth more than $452,454 as of July 22nd. This net worth estimate does not reflect any other assets that Dr. Carter may own. Learn More about Todd Alfred Carter's net worth.
How do I contact Todd Alfred Carter?: The corporate mailing address for Dr. Carter and other Voyager Therapeutics executives is 75 SIDNEY STREET, CAMBRIDGE MA, 02139. Voyager Therapeutics can also be reached via phone at (857) 259-5340 and via email at [email protected]. Learn More on Todd Alfred Carter's contact information.
Has Todd Alfred Carter been buying or selling shares of Voyager Therapeutics?: Todd Alfred Carter has not been actively trading shares of Voyager Therapeutics during the last ninety days. Most recently, Todd Alfred Carter sold 4,174 shares of the business's stock in a transaction on Tuesday, February 24th. The shares were sold at an average price of $3.76, for a transaction totalling $15,694.24. Following the completion of the sale, the insider now directly owns 145,718 shares of the company's stock, valued at $547,899.68. Learn More on Todd Alfred Carter's trading history.
Who are Voyager Therapeutics' active insiders?: Voyager Therapeutics' insider roster includes Julie Burek (VP), Todd Carter (Chief Scientific Officer), Alfred Sandrock (President and Chief Executive Officer), and Robin Swartz (Chief Business Officer and Chief Operating Officer). Learn More on Voyager Therapeutics' active insiders.
Are insiders buying or selling shares of Voyager Therapeutics?: In the last year, insiders at the sold shares 9 times. They sold a total of 68,960 shares worth more than $269,884.60. The most recent insider tranaction occured on April, 2nd when CEO Alfred Sandrock sold 11,511 shares worth more than $44,547.57. Insiders at Voyager Therapeutics own 12.7% of the company. Learn More about insider trades at Voyager Therapeutics.
Information on this page was last updated on 4/2/2026.

Todd Alfred Carter Insider Trading History at Voyager Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
2/24/2026	Sell	4,174	$3.76	$15,694.24	145,718
2/10/2026	Sell	3,525	$3.85	$13,571.25	153,193
1/14/2025	Sell	1,191	$5.13	$6,109.83	86,436
1/17/2024	Sell	1,266	$7.18	$9,089.88	53,094
9/15/2023	Sell	10,500	$8.16	$85,680.00	54,360
7/6/2023	Sell	5,500	$10.80	$59,400.00	59,860
3/20/2023	Sell	2,193	$7.76	$17,017.68	65,360
2/17/2023	Sell	738	$7.45	$5,498.10	67,553
2/13/2023	Sell	797	$7.67	$6,112.99	34,291
1/17/2023	Sell	1,106	$9.85	$10,894.10	35,088

Todd Alfred Carter Buying and Selling Activity at Voyager Therapeutics

Voyager Therapeutics Company Overview

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.

Today's Range

Now: $3.11

$3.06

$3.12

50 Day Range

MA: $3.59

$3.04

$4.24

2 Week Range

Now: $3.11

$2.88

$5.55

Volume

241,774 shs

Average Volume

657,959 shs

Market Capitalization

$187.60 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.27